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PENENTUAN MEKANISME TINDAKAN ASID KAFEIK FENETIL ESTER 
(CAPE) MELALUI PROFIL TRANSKRIPTOM Burkholderia pseudomallei 
STRAIN K96243  
ABSTRAK 
Burkholderia pseudomallei adalah sejenis bakteria patogen Gram-negatif yang 
menyebabkan melioidosis, sejenis penyakit berbahaya dan endemik di kawasan Asia 
Tenggara, terutamanya Malaysia dan Thailand. B. pseudomallei mempunyai kelaziman 
rintangan terhadap pelbagai kelas antibiotik, seperti aminoglikosida, makrolida, β-laktam, 
dan sefalosporin. Kewujudan protein pam pembawa keluar yang mampu mengepam 
keluar antibiotik dari sel serta kebolehtelapan membran bakteria yang rendah yang 
menghalang penetrasi antibiotik menyumbang kepada kelaziman rintangan antibiotik. 
Faktor-faktor tersebut merumitkan proses terapi antibiotik untuk penyakit melioidosis. 
Oleh itu, antara strategi berkesan untuk meminimumkan tahap rintangan bakteria adalah 
menggunakan sebatian yang dapat menguatkan aktiviti antibiotik. Dalam kajian ini, 
potensi asid kafeik serta terbitannya iaitu asid kafeik fenetil ester (CAPE), asid klorogenik, 
dan asid kafeik fenetil amida (CAPA) untuk bertindak sebagai pembantu antibiotik 
(adjuvan) telah dinilai. Hasil kajian mendapati gabungan kepekatan sub-hambatan CAPE 
dengan gentamisin atau kanamisin berjaya mengurangkan MIC antibiotik tersebut dalam 
B. pseudomallei sebanyak empat kali ganda dan dua kali ganda. Imbasan mikroskopi 
elektron menunjukkan keadaan sel bakteria yang dirawat dengan CAPE terjejas dan 
mengalami perubahan fenotip yang ketara, seperti kecacatan bentuk, penyusutan saiz, 
serta pembentukan bonjolan dan lekukan pada membran. Untuk memahami dengan lebih 
mendalam tentang mekanisme tindakan CAPE, pemprofilan transkrip RNA digunakan 
xviii 
 
untuk menentukan kesan pendedahan CAPE kepada bakteria. Melalui analisis 
transkriptom B. pseudomallei yang telah dirawat dengan CAPE, sebanyak 658 gen telah 
dikenal pasti mengalami perbezaan dalam regulasi berbanding dengan sel yang tidak 
terawat. Antara gen yang dikenal pasti memainkan peranan dalam tindak balas kepada 
CAPE adalah mekanisme pemerolehan zat besi, seperti biosintesis dan pengangkutan 
siderofor, enzim reduktase ferrat, protein pengangkut zat besi, dan protein penyimpan zat 
besi. Ini menunjukkan bahawa CAPE mungkin bertindak sebagai kelator besi yang 
menyebabkan bakteria mengalami kekurangan zat besi. Kelompok gen lain yang 
umumnya dikaitkan dengan keterbatasan zat besi, seperti metabolisme nitrogen, sistem 
rembesan bakteria, fosforilasi oksidatif, dan pernafasan juga mengalami perbezaan 
regulasi dalam sel yang dirawat dengan CAPE. Gen yang mengekod protein pam 
pembawa keluar, protein porin, dan enzim yang terlibat dengan proses degradasi asid 
hidroksisinamat mengalami peningkatan regulasi, menunjukkan bahawa bakteria cuba 
mengehadkan penetrasi CAPE dan mengurangkan kepekatannya di dalam sel. Selain itu, 
regulasi gen yang mengekod pengatur global Crp/Fnr, protein yang mengawal 
pembahagian kromosom dan sel, dan protein yang mengawal pembentukan lapisan 
peptidoglikan adalah antara yang mengalami peningkatan regulasi, manakala regulasi 
terhadap gen yang mengekod protein mengandungi besi, sistem pengambilan heme, dan 
pengatur global Fis mengalami pengurangan. Data yang diperoleh daripada RNA-seq 
disahkan melalui PCR-transkripsi terbalik kuantitatif (qRT-PCR). Hasil kerja ini 
menunjukkan bahawa mekanisme tindakan CAPE dalam B. pseudomallei adalah pelbagai, 
dan mod utama CAPE adalah menghalang penyerapan zat besi serta merencat integriti 
membran B. pseudomallei.  
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ELUCIDATING THE MECHANISM OF ACTION OF CAFFEIC ACID 
PHENETHYL ESTER (CAPE) VIA TRANSCRIPTOMIC PROFILING OF 
Burkholderia pseudomallei STRAIN K96243 
ABSTRACT 
Burkholderia pseudomallei is a Gram-negative bacterial pathogen that causes 
melioidosis, a life-threatening disease endemic in the regions of Southeast Asia, 
particularly Malaysia and Thailand. B. pseudomallei is intrinsically resistant to wide 
classes of clinically useful antibiotics, such as aminoglycosides, macrolides, β-lactams, 
and older-generation cephalosporins. The expression of multiple efflux pumps and the 
low permeability of the bacterium’s outer membrane contribute to its multidrug-resistant 
(MDR) traits, which further complicate the therapeutic management for melioidosis. 
Thus, a promising strategy to minimize the resistance level of MDR bacteria is by the use 
of non-antibiotic helper compounds as an adjuvant to potentiate the antimicrobial activity 
of antibiotics. In this study, the potential of caffeic acid and its derivatives, i.e. caffeic acid 
phenethyl ester (CAPE), chlorogenic acid, and caffeic acid phenethyl amide (CAPA) to 
act as antibiotic potentiators in B. pseudomallei were evaluated. We demonstrated that the 
combination of a sub-inhibitory concentration of CAPE with gentamicin or kanamycin 
significantly reduced the MIC of these antibiotics in B. pseudomallei by four-fold and 
two-fold, respectively. Scanning electron microscopy further revealed that the fitness of 
the cells treated with CAPE were compromised, with apparent phenotypic changes to the 
cell morphology and disruption in the membrane architecture, such as shrunken, deformed 
shape and formation of membrane blebs and dimples. To decipher the mechanism of 
action of CAPE, RNA-sequencing was utilized to determine its impact of exposure based 
xx 
 
on the transcriptional profiles of B. pseudomallei. Transcriptome analysis of CAPE-
treated cells indicated significant modulation of gene expression, of which 658 genes were 
differentially expressed. The genes responsible for iron acquisition mechanisms were 
highly induced, including siderophore biosynthesis and uptake, ferric reductases, iron 
transport/utilization-like proteins, and iron storage proteins, implying that the bacterium 
was deprived of iron. The exposure of CAPE to the nutrient-rich medium might have 
rendered iron selectively unavailable for the bacterium, which suggest that CAPE might 
be acting as an iron chelating agent. Other clusters of genes that are generally associated 
with the condition of iron limitation, such as those implicated in nitrogen metabolism 
pathway, bacterial secretion system, oxidative phosphorylation, and respiration were also 
differentially regulated in CAPE-treated cells. Genes encoding efflux pump proteins, 
porin-related proteins, and hydroxycinnamate degradation enzyme were upregulated, 
indicating that the bacterium likely attempted to limit the penetration of CAPE and reduce 
its intracellular concentration. In addition, the expression of genes encoding global 
regulator Crp/Fnr, partitioning protein, and murein-associated proteins were induced, 
whereas genes encoding iron-containing proteins, heme uptake system and global 
regulator Fis were downregulated. The data obtained from RNA-seq were corroborated 
by quantitative reverse transcription-PCR (qRT-PCR). The results of the present work 
indicate that the mechanisms of action of CAPE in B. pseudomallei are multifarious, in 





CHAPTER 1: INTRODUCTION 
1.1 Background of study and problem statement 
The Gram-negative Burkholderia pseudomallei is a facultative intracellular 
pathogen that causes severe infections with a broad spectrum of illnesses known as 
melioidosis. Melioidosis is highly endemic in Southeast Asia, particularly Malaysia 
and Thailand, as well as in northern Australia and several regions in the subtropics or 
tropics (Leelarasamee, 2000; Mukhopadhyay et al., 2011; Puthucheary, Lin, & Yap, 
1981; Vadivelu et al., 1997; Vuddhakul et al., 1999). B. pseudomallei is an 
environmental saprophyte that naturally resides in wet soil, stagnant water, and rice 
paddy areas in the prevalent regions (Dance, 1991, 2002; White, 2003). Although it is 
a saprophytic bacterium, it is capable of causing an opportunistic infection that could 
rapidly advance to a fatal illness, especially in patients with comorbidities. Infection 
commonly occurs through inhalation or inoculation of bacteria in the skin breaks or 
wounds upon contact with contaminated soil or water.  
B. pseudomallei is a causative factor for community-acquired pneumonia and 
septicemia in some of the endemic regions, in which mortality rate is high despite 
intensive antibiotic treatments (Boonsawat et al., 1990; Chaowagul et al., 1989; Currie 
et al., 2000; Dance, 1991; Elliott et al., 2005). Clinical presentations of melioidosis are 
wide-ranging and may resemble other types of disease, thus complicating its diagnosis. 
General manifestations of melioidosis may include acute pulmonary infection, 
localized or chronic suppurative infection, acute septicemia or others. It may also 
present as an asymptomatic infection which the bacterium can stay latent for a long 
period of time before clinical symptoms are apparent.  
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B. pseudomallei is able to survive in toxic conditions and is resistant to many 
antimicrobials or disinfectants used in hospitals and household settings. The bacterium 
is intrinsically resistant to wide classes of antibiotics, particularly aminoglycosides, β-
lactams, macrolides, rifamycins, colistin, and older-generation cephalosporins (Dance 
et al., 1989; Jenney et al., 2001). The resistance of B. pseudomallei towards a broad 
spectrum of clinically useful antibiotics presents a challenge in the treatment of this 
disease. Melioidosis is difficult to manage as infection can still result in a rapid fatal 
outcome even with the use of appropriate antimicrobial agents. Besides, antibiotics 
typically used in the first-line treatment of Gram-negative bacterial sepsis such as 
aminoglycosides, ampicillin, or amoxicillin are clinically ineffective in treating 
melioidosis. Treatment of B. pseudomallei also proves to be challenging due to the 
need for a prolonged course of complex antimicrobial therapy (Cheng & Currie, 2005; 
Woo et al., 2003). The treatment course for melioidosis comprises two phases: an 
intensive acute phase and an eradication phase. The first phase of therapy involves 
intravenous administration of ceftazidime, meropenem, or imipenem for at least 10 to 
14 days. The second phase of therapy involves oral administration of trimethoprim–
sulfamethoxazole (TMP/SMX) for a minimum of three to six months (Wiersinga, 
Currie, & Peacock, 2012).  
Antibiotic treatments that adhere strictly to the recommended procedures 
usually result in better outcomes; however, the rates of failure in clinical therapy of 
melioidosis still remain high (Dance, 2014; Pitman et al., 2015). The bacterium’s 
intrinsic and acquired resistance to antimicrobial agents are among the factors that 
contribute to treatment failures. B. pseudomallei develops resistance to antibiotics via 
several known mechanisms, such as drug efflux, target modification, enzymatic 
inactivation of drugs, and reduced permeation (Schweizer, 2012a).  
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Developing novel classes of antibiotic that have a new mechanism of action is 
very challenging, costly, and time-consuming. Many new antibiotics that have entered 
the market are derivatives of old drugs that hold the same key function, which experts 
believe that these second, third, or fourth generations of antibiotics could only extend 
the drugs’ efficacy by several years (reviewed in Buckland, 2017). In fact, the progress 
in the discovery of novel antibiotics has slowed down since 1980s. In recent years, a 
small number of novel antibiotics have been introduced for the treatment of Gram-
positive infections; however, no novel classes of antibiotics have been successfully 
produced for Gram-negative bacteria in the last 40 years (reviewed in Buckland, 2017; 
World Health Organization, 2014). This was previously due to the perception that the 
existing armamentarium of antibiotics were sufficient to control bacterial infections. 
Other factors include huge economic cost and low investment in research and 
development (R&D) on novel antimicrobials, since major pharmaceutical companies 
have shifted their focus towards more profitable diseases (reviewed in González-Bello, 
2017). Thus, a good alternative in tackling antimicrobial resistance would be 
minimizing the impact and emergence of antibiotic resistance. This can be achieved 
through the use of antibiotic adjuvants (also termed ‘antibiotic potentiators’ or 
‘resistance breakers’), such as efflux pumps inhibitors, β-lactamase inhibitors, or outer 
membrane permeabilizers. Adjuvants are co-administered with antibiotics to inhibit 
bacterial mechanisms of resistance and potentiate the antimicrobial action of 
antibiotics (Farha & Brown, 2013; Gill, Franco, & Hancock, 2015; Kalan & Wright, 
2011; Worthington & Melander, 2013). This combination approach has the potential 
to reinstate the clinical efficacy of existing antibiotics, broaden the antibiotic spectrum, 
minimize the effective dose of antibiotics required in a treatment, and render 
multidrug-resistant (MDR) bacteria susceptible to antibiotics. As antibiotic adjuvants 
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generally possess weak or no antibacterial activity, bacteria will not develop resistance 
towards these compounds.  
The use of antibiotic adjuvants is a promising approach to decrease the level of 
resistance in B. pseudomallei and restore the effectiveness of antibiotics it is currently 
resistant to. Antibiotic adjuvants that work as efflux pump inhibitors might be the best 
candidate, since extrusion of antibiotics by efflux systems is the major mechanism of 
resistance in this bacterium (Schweizer, 2012b). Efflux inhibition strategies can be 
accomplished in several ways, for instance, disrupting the source of energy of the 
pumps, obstructing the interaction between different components of a multi-segmented 
pump, blocking the binding of antimicrobial agents to the cytoplasmic membrane 
pumps, or targeting the regulatory genes that control the expression of efflux pumps 
(Pagès & Amaral, 2009; Poole & Lomovskaya, 2006). An efflux pump inhibitor (EPI) 
is characterized by its modulating ability to specifically impede the export of 
antibiotics by bacterial efflux systems, which sometimes might also hinder the export 
of physiological substrates of the pumps. The rising prevalence of MDR strains has 
reduced the clinical efficacy of many antibacterial agents; hence, the ability of EPIs to 
circumvent the efflux of antibiotics will reinstate the clinical utility of several older 
compounds, increase the potency of antimicrobial agents, and prevent further 
development of multidrug resistance (reviewed in Kamicker et al., 2008).  
Plant-based compounds have emerged as interesting candidates for potential 
antibiotic adjuvants, which in turn have motivated huge scientific interest in the 
discovery of novel EPIs from natural sources (Abreu et al., 2016; Abreu et al., 2017; 
Chusri et al., 2009; Lacmata et al., 2012; Noumedem et al., 2013). Indeed, bioactive 
compounds derived from natural products have been extensively used for 
pharmaceutical and medicinal purposes due to their highly recognized benefits. Plants 
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and herbs have been used since primeval times for the treatment of various ailments 
including bacterial, viral and fungal infections (Dupont et al., 2006; Temrangsee, 
Kondo, & Itharat, 2011). Plant resources provide a vast repertoire of structurally 
complex, chemically diverse, and biologically active phytochemicals. Phenolic 
compounds like caffeic acid and its derivatives are among the bioactive 
phytochemicals that are abundantly found across the plant kingdom. They occur 
naturally in food such as fruits, grains, olive oil, tea, coffee, vegetables and many 
others (Higdon & Frei, 2006). They have been gaining increasing attention for their 
broad spectrum pharmacological attributes, which encompass antibacterial, antiviral, 
anti-diabetic, anti-inflammatory, antioxidant, anticancer, and immunomodulatory 
effects (Celik & Erdogan, 2008; Celik, Erdogan, & Tuzcu, 2009; Challis & Bartlett, 
1975; Gülçin, 2006; Ikeda et al., 2011; Tsai et al., 2012). Interestingly, some of the 
derivatives of caffeic acid have also been reported to demonstrate strong efflux 
inhibition activities in Gram-positive bacteria like Staphylococcus aureus (Santos et 
al., 2018; Fiamegos et al., 2011; Michalet et al., 2007). This suggests the potential of 
caffeic acid derivatives as good EPI candidates considering they are capable of 
inhibiting MDR efflux pumps, and are readily available and non-toxic for human 
consumption. 
Due to the beneficial prospects of caffeic acid derivatives, the present study 
was initiated to explore their potential role as antibiotic adjuvants, particularly as 
efflux pump inhibitors in Gram negative B. pseudomallei. One-concentration 
combination test using tetrazolium microplate assay (TEMA) was employed to 
investigate whether the combination of a particular test compound with antibiotics 
caused any reduction in minimum inhibitory concentration (MIC) of the antibiotic. 
The main focus of this work was to unravel the mechanism of action of a selected test 
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compound, especially on the regulation of gene expression in B. pseudomallei in 
response to the compound. To achieve this, RNA sequencing (RNA-seq) was utilized 
to identify the set of protein coding mRNAs that were differentially expressed between 
two different experimental conditions. Next-generation sequencing (NGS) 
technologies such as RNA-seq have revolutionized transcriptomic research by 
producing high-throughput datasets with unprecedented accuracy, sensitivity and 
precision. It has become the preferred method for gene expression profiling and is 
rapidly replacing conventional methods like microarrays (Ozsolak & Milos, 2011; 
Shendure & Ji, 2008; Wang, Gerstein, & Snyder, 2009).  
1.2 Research objectives 
This study was aimed at evaluating the potential efflux inhibitory activity of 
caffeic acid, chlorogenic acid, caffeic acid phenethyl amide (CAPA), and caffeic acid 
phenethyl ester (CAPE) on B. pseudomallei strain K96243. Gene expression profiles 
of B. pseudomallei from RNA-seq data derived from control and treated bacterial cells 
were generated in order to investigate if a selected test compound (CAPE) modulates 
the expression of multidrug efflux pumps in B. pseudomallei, and to reveal the effects 
that the compound exerts at the transcriptional level. This enables the identification of 
a set of transcripts that were differentially expressed and allows a better understanding 
on the possible modes of action of the compound. The main objectives of this present 
study are outlined as follows: 
Objective 1: To assess the antimicrobial activity and efflux inhibition activity of 
caffeic acid, chlorogenic acid, CAPE, and CAPA against B. 




Objective 2: To investigate if the selected compound (CAPE) caused any observable 
changes to the cell morphology and membrane architecture of B. 
pseudomallei using scanning electron microscope (SEM) visualization. 
Objective 3: To decipher and elucidate the mechanism of action of CAPE via 







CHAPTER 2: LITERATURE REVIEW 
2.1 A brief overview on antimicrobial resistance 
Antimicrobial resistance is becoming a major public health crisis as its global 
incidence continues to rise (Lushniak, 2014; Michael, Dominey-Howes, & Labbate, 
2014). The World Health Organization (WHO) has listed antimicrobial resistance as 
one of the biggest health threats in this century (World Health Organization, 2014). It 
poses adverse consequential impacts on the management and treatment of infectious 
diseases, as drugs of high clinical importance are gradually becoming less effective 
against multidrug-resistant (MDR) pathogens. In addition to the increasing levels of 
resistance, the rate of which newer antimicrobials are being discovered has also 
severely dropped (Laxminarayan, 2014). If the resistance trends continue to persist in 
this current state, a post-antibiotic era may perhaps become imminent (Ventola, 2015b, 
2015a). Thus, understanding the underlying mechanisms that drive bacterial resistance 
to antibiotics and developing novel therapeutic approaches are imperative in order to 
curb the emergence of MDR strains.  
The outstanding genetic plasticity of bacteria enables them to adapt and 
respond to various threats, including the harmful effects of antimicrobial compounds. 
Bacterial resistance mechanisms are extremely crucial for their continuous adaptability 
and survival. Through millions of years of evolution, bacteria have evolved complex 
adaptive mechanisms to survive constant exposure to naturally occurring 
antimicrobials in the environment. These mechanisms of resistance are attained 
through mutability or transfer of mobile genetic elements (reviewed in Munita & 
Arias, 2016). Furthermore, natural selection has resulted in the proliferation and spread 
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of drug-resistant bacteria, as their drug-sensitive competitors are eradicated under 
antibiotics stress (Read & Woods, 2014).  
2.2 Mechanisms of antimicrobial resistance in bacteria 
The current arsenal of antibiotics work against bacteria through several modes 
of action, such as targeting bacterial DNA replication and repair (RNA polymerase, 
DNA gyrase), cell-wall biosynthesis, membrane structure, protein synthesis (subunit 
30S or 50S of ribosome), and folic acid metabolism (reviewed in González-Bello, 
2017). Development of bacterial resistance to antibiotics can be intrinsic or acquired. 
The low permeability of membrane barriers, the presence of multidrug transporters 
that can extrude antibiotics, and the lack of target structures for specific antimicrobial 
actions are among the fundamental characteristics of intrinsic resistance in bacteria 
(Putman, van Veen, & Konings, 2000; Taylor-Robinson & Bébéar, 1997). On the 
contrary, acquired resistance is primarily caused by chromosomal mutation in the 
genome of the bacteria or acquisition of antibiotic resistance determinants through 
horizontal gene transfer (Nikaido, 1994). The fundamental mechanisms of bacterial 
antibiotics resistance involve several major modes:  
(1) enzymatic inactivation of antibiotics (Wright, 2005),  
(2) target site modification (Lambert, 2005),  
(3) active efflux of antibiotics, and changes in membrane permeability (Kumar 
& Schweizer, 2005).  
2.2.1 Enzymatic inactivation of drugs 
To inactivate antibiotic molecules, many Gram-positive and Gram-negative 
bacteria are capable of producing enzymes that can degrade or modify the antibiotics, 
thus rendering them ineffective. For instance, resistance to penicillin and 
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cephalosporin is mediated through the cleavage of their β-lactam ring by hydrolytic 
enzymes called β-lactamases; the destruction of the amide bond of β-lactam ring 
subsequently leads to the degradation of the antibiotics (Bonnet, 2004; Bush, Jacoby, 
& Medeiros, 1995; Kotra & Mobashery, 1999; Poole, 2004). Antimicrobial 
compounds like chloramphenicol, macrolides, aminoglycosides, rifampicin, or 
streptogramin can be inactivated by transferase enzymes through phosphorylation 
(Matsuoka & Sasaki, 2004; Nakamura et al., 2000; Yazawa et al., 1994), acetylation 
(Allignet & el Solh, 1995; Schwarz et al., 2004; Vetting et al., 2004), ribosylation 
(Houang et al., 2003), or nucleotidylation of the antibiotics molecule (Brisson-Noel et 
al., 1988; Pedersen, Benning, & Holden, 1995). The addition of chemical moieties 
through  enzymatic modification affects the binding of antibiotics to their target which 
subsequently impedes their activity (Strateva & Yordanov, 2009; Tolmasky, 2000). 
2.2.2 Target site modification 
Modification of antibiotics target site is another common mechanism of drug 
resistance in bacteria. This mechanism usually involves target alteration through 
mutational changes which cause reduction in the affinity of the binding site (Spratt, 
1994). A well-characterized example is the amino acid alterations in bacterial 
penicillin-binding proteins (PBPs) which lead to the increase in resistance to β-lactam 
antibiotics such as penicillin, amoxicillin, and ampicillin in several bacterial strains 
(Dowson, Coffey, & Spratt, 1994; Kosowska et al., 2004; Nagai et al., 2002). 
Resistance to fluoroquinolones is conferred by the presence of mutations in the 
structural genes that alter enzymes like DNA gyrase or topoisomerase IV, which 
prevents antibiotics action on the targeted enzymes (Ince et al., 2002; Khodursky, 
Zechiedrich, & Cozzarelli, 1995). 
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2.2.3 Drug efflux 
Bacteria can actively efflux antibiotics out of the cells and regulate the 
permeability of their membranes, as part of their fundamental mechanisms of drug 
resistance (Nikaido, 1994). The extrusion of antimicrobial agents out of the bacterial 
intracellular milieu is due to the presence of membrane transporter proteins, generally 
known as efflux pumps. These efflux pumps are capable of transporting out broad 
classes of antimicrobials, including aminoglycosides, macrolides, fluoroquinolones, 
and tetracycline, thus lowering antibiotics concentrations inside the cells (Nikaido & 
Zgurskaya, 1999; Webber & Piddock, 2003). They also possess a variety of other 
physiological functions (Piddock, 2006). Bacterial efflux pumps can either specifically 
extrude only one class of antibiotics or non-specifically extrude multiple classes of 
antibiotics, hence triggering the emergence of MDR phenotypes in bacteria (Poole, 
2005). There are five classes of bacterial efflux pump systems, which include the 
resistance-nodulation-division (RND) superfamily, the major facilitator (MFS) 
superfamily, the multidrug and toxic compound extrusion (MATE) family, the small 
multidrug resistance (SMR) family, and the ATP-binding cassette (ABC) superfamily. 
The ABC superfamily is a primary transporter which utilizes ATP to drive the binding 
and extrusion of substrates (Davidson & Maloney, 2007), whereas the RND, MFS, 
MATE, and SMR families are secondary transporters which depend on proton motive 
force as a source of energy (Forrest, Krämer, & Ziegler, 2011). 
2.2.4 Reduced permeation 
In addition to efflux mechanism, bacterial resistance can be further enhanced 
through changes in membrane permeability. Gram-positive bacteria such vancomycin-
intermediate resistant Staphylococcus aureus (VISA) strains are capable of increasing 
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their cell wall thickness to restrict drug penetration, which significantly reduces their 
susceptibility to vancomycin (Cui et al., 2000). The outer membranes of Gram-
negative bacteria are made up of phospholipids in the inner leaflet and 
lipopolysaccharides in the outer leaflet, which act as barriers against the penetration of 
lipophilic toxic compounds, including antibiotics (Nikaido, 2003). Diffusion and 
passive transport across the outer membrane are achieved through water-filled 
channels called porins (Lambert, 2002). To limit the influx of hydrophilic 
antimicrobial agents, bacteria can reduce membrane permeability by regulating the 
expression levels of porins to decrease the number or change the types and selectivity 
of the porin channels (Chevalier, Pagès, & Malléa, 1999; Dé et al., 2001; Hancock & 
Brinkman, 2002). This will subsequently decrease the rate of diffusion of hydrophilic 
compounds such as chloramphenicol, β-lactams, tetracycline, and certain 
















2.3 Causes of antimicrobial resistance and possible ways to reduce it 
Antimicrobial resistance is a naturally occurring process; however, the 
inappropriate use of antimicrobial agents tends to accelerate its development in 
microorganisms through selective pressure. Indeed, continuous overdependence on 
antibiotics and their uncontrolled usage are the main reasons for the upsurge of bacteria 
that are predominantly resistant to antibiotics (Davies, 1996). Burkholderia spp. such 
as B. pseudomallei are among the pathogens of clinical significance due to their 
intrinsic resistance to multiple antimicrobial agents and their capacity to acquire 
complex multidrug resistance (Poole, 2001).  
The lack of progress in the development of novel antimicrobials is the cause 
for the current shortage of new antimicrobial options that can substitute ineffective 
drugs. This highlights the importance of restoring and maintaining the efficacy of 
existing antimicrobial agents. A number of strategies have been initiated to control and 
reverse antimicrobial resistance, such as co-administrating antibiotics with molecules 
or adjuvants that can block a targeted resistance machinery (Baym, Stone, & Kishony, 
2016), strengthening the activity of antibiotics through chemical or structural 
modifications (Kondo & Hotta, 1999; Malabarba, Nicas, & Thompson, 1997; 
Sztaricskai et al., 1999), and suppressing the mechanisms that confer persistence (Chen 
et al., 2011; Rutherford & Bassler, 2012; Smith & Romesberg, 2007) or virulence in 








2.4 Burkholderia pseudomallei: Introduction and profiles 
B. pseudomallei is a betaproteobacteria which belongs to the family 
Burkholderiaceae. It is characterized as an aerobic, non-spore forming, oxidase-
positive, motile bacillus with one or more polar flagella. It is a small-sized bacterium 
that measures approximately 2-5 µm in length and 0.4-0.8 µm in diameter. The Gram 
stain of this bacterium shows Gram-negative rods that have bipolar staining with a 
characteristic “safety pin” appearance. During the early days, it was formerly known 
by various names such as Bacillus pseudomallei, Bacillus whitmorii, Malleomyces 
pseudomallei, and Pseudomonas pseudomallei (Cheng & Currie, 2005). In 1992, 
Yabuuchi and his colleague proposed the transfer of seven species from the 
Pseudomonas group to the new Burkholderia genus, which included Pseudomonas 
mallei, Pseudomonas pseudomallei, Pseudomonas cepacia, Pseudomonas 
solanacearum, Pseudomonas gladioli, Pseudomonas caryophylli, and Pseudomonas 
pickettii; hence, the name Pseudomonas pseudomallei was subsequently changed to 
Burkholderia pseudomallei (Yabuuchi et al., 1992). 
The bacterium is a soil saprophyte that thrives in wet soil, stagnant water, and 
rice-farming areas (White, 2003). It grows optimally at a temperature of 37 °C or 42 
°C in a neutral or mildly acidic soil medium with pH 6.5 to 7.5 (Chen et al., 2003). In 
laboratory settings, it is a non-fastidious organism that grows readily on a variety of 
nutrient media such as Ashdown’s agar, Luria medium, Mueller Hinton broth, 
MacConkey agar, and blood agar. Colony morphology on agar plate is characterized 
by smooth, translucent, round, and slightly raised appearance after an overnight 
incubation at 37 °C. Aging colonies show dry, rough and wrinkled morphology with a 
metallic appearance. The bacterial cultures also exude an earthy, musty odor. 
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B. pseudomallei is considered a potential agent of biological warfare due to its 
capability to spread infection by aerosol transmission (Rotz et al., 2002), in addition 
to its high virulence, mortality rate, and resistance to a wide range of antimicrobial 
agents. Since 2015, the U.S. Centers for Disease Control and Prevention (CDC) has 
classified it as a category B bioterrorism agent (https://emergency.cdc.gov/agent/ 
agentlist-category.asp). B. pseudomallei can survive in harsh environmental 
conditions, including nutrient-deprived settings such as low availability of iron 
(Hantrakun et al., 2016), limited oxygen (Hamad et al., 2011; O’Rourke et al., 2017), 
and in dehydrated soil with low moisture content (Tong et al., 1996). It can persist in 
highly acidic environment of pH 4.5 (Dejsirilert et al., 1991), in detergent and 
disinfectant solutions (reviewed in Cheng & Currie, 2005; Gal et al., 2004), and in 
high concentrations of salt or oxidative agents. In 2010, it was discovered that B. 
pseudomallei was able to survive in distilled water without any nutrients for at least 
16 years, which indicates the ability of the bacterium to endure and adapt in extreme 
conditions (Pumpuang et al., 2011). 
2.4.1 Genome characteristics of B. pseudomallei 
The complete genome of B. pseudomallei strain K96243 has been sequenced 
by The Wellcome Sanger Institute (Holden et al., 2004). The genome is 7,247,547 
basepairs (bp) in size with a G+C content of 68.06%. It is one of the largest and most 
complex prokaryotic genomes, harboring two circular chromosomes of 4,074,542 bp 
and 3,173,005 bp, respectively. The larger replicon, known as chromosome 1, consists 
of 3,460 coding sequences, 53 transfer RNAs (tRNAs) and 9 ribosomal RNAs 
(rRNAs), whereas chromosome 2 contains 2,395 coding sequences, 8 tRNAs and 3 
rRNAs. Chromosome 1 encodes proteins essential for core cellular functions such as 
cell growth, central metabolism, macromolecular biosynthesis, chemotaxis, and 
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mobility. Chromosome 2 encodes proteins related to accessory functions which are 
important for adaptation and survival ability of B. pseudomallei, such as regulation of 
laterally acquired DNA, secondary metabolism, iron acquisition, and osmotic 
protection (Holden et al., 2004). The regions of genomic island (GI) which make up 
6.1% of B. pseudomallei genome contain mobile genetic elements acquired through 
horizontal gene transfer. The GI regions are an important evolutionary feature for B. 
pseudomallei virulence (Holden et al., 2004). A large proportion of B. pseudomallei 
genes are still unannotated or uncharacterized. 
The genome of B. pseudomallei is made up of various gene clusters that are 
important for environmental survival and virulence of the bacterium. Quorum sensing 
(Ulrich et al., 2004), pathogenicity islands, protein secretion systems (type II, type III, 
type IV, and type VI secretion systems) (Burtnick et al., 2011; DeShazer et al., 1999; 
French et al., 2011; Gong et al., 2011; Schwarz et al., 2014; Stevens et al., 2002; 
Winstanley, Hales, & Hart, 1999), drug resistance determinants, and cell surface 
adhesion (Holden et al., 2004) are among the factors implicated in the virulence and 
pathogenesis of B. pseudomallei. The type III secretion systems (TTSS) are one of the 
most significant virulent determinants of B. pseudomallei, in which the secretion of 
effector proteins into the cytosol of target cells through its needle-like apparatus is a 
requisite factor in the invasion of host cells (Muangsombut et al., 2008; Stevens et al., 
2002). Certain surface polysaccharides, such as the O-antigenic polysaccharide moiety 
of B. pseudomallei lipopolysaccharides play an important role in facilitating 
intracellular survival and bacterial evasion from host innate immune systems 
(Arjcharoen et al., 2007). The capsular polysaccharides help protect B. pseudomallei 
from phagocytic mediated killing, in which it subsequently increases the extracellular 
persistence of the bacterium (Reckseidler-Zenteno, DeVinney, & Woods, 2005). Other 
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factors such as flagella (Chua, Chan, & Gan, 2003; Chuaygud et al., 2008) and type 
IV pili (Essex-Lopresti et al., 2005) are necessary to facilitate bacterial adherence and 
invasion of host cells. 
2.5 History of melioidosis 
B. pseudomallei is an etiological agent of melioidosis (Dance, 1991), an acute 
and life-threatening disease endemic in Southeast Asia, northern Australia, and 
tropical regions (Rolim et al., 2005; Chaowagul et al., 1989; Currie, Dance, & Cheng, 
2008; Howe, Sampath, & Spotnitz, 1971; Kanungo et al., 2002; Puthucheary, 
Parasakthi, & Lee, 1992; Sexton et al., 1993). This bacterium is known to cause 
potentially fatal infection in both human and animals, including cows, goats, sheep, 
horses, pigs, and others (Dance, 1991; Sprague & Neubauer, 2004). The disease was 
first discovered in Rangoon, Burma by pathologist Alfred Whitmore and his assistant 
Krishnaswami in 1911, of which they initially described it as “glanders-like” disease 
(Whitmore, 1913; Whitmore & Krishnaswami, 1912). Stanton and Fletcher then 
proposed the name melioidosis, which was derived from the Greek words “melis” 
(distemper of asses) and “eidos” (resemblance) on account of several clinical and 
pathophysiological similarities between the disease and glanders  (Stanton & Fletcher, 
1921). Melioidosis was first documented in Malaya by Fletcher following an outbreak 
involving laboratory animals at the Institute of Medical Research, Kuala Lumpur in 
1913 (Stanton & Fletcher, 1925). Some of the earliest cases of human melioidosis were 
described by Stanton based on two occurrences in Kuala Lumpur in 1917 (Stanton, 





2.5.1 Clinical presentation and physiognomy of melioidosis 
Melioidosis can be categorized into the acute, subacute, or chronic forms of 
illness (Howe et al., 1971). It has a very broad clinical spectrum, varying from 
asymptomatic infection and localized abscess formation at one end of the spectrum, to 
disseminated abscesses in multiple organs, fulminant sepsis, shock, and death at the 
other end of the spectrum (Currie et al., 2004; Jain et al., 2007; Malczewski et al., 
2005; Silbermann et al., 1997; Tiangpitayakorn et al., 1997; Walsh et al., 1995; White, 
2003; White et al., 1989; Whitmore & Krishnaswami, 1912). The most aggressive 
form of melioidosis is acute melioidosis, which represents more than 85% of the 
reported clinical cases (Currie et al., 2010). Mortality rate due to melioidosis is 
noticeably higher in Southeast Asian countries, with 33% to 65% of documented cases 
compared to other endemic regions such as Northern Australia (14%) and India (9.5%) 
(reviewed in Kingsley et al., 2016; Limmathurotsakul et al., 2010). The most common 
clinical manifestations of melioidosis are acute/subacute pneumonia, acute febrile 
illness, localized skin or soft tissue abscess, and septicemia (Currie et al., 2000; 
Kingsley et al., 2016; Smith et al., 1987; White, 2003). Acute septicemic infections 
often quickly result in death despite intensive antibiotic therapy and have been the 
causal factor for significant mortality and morbidity in Southeast Asia (Chaowagul et 
al., 1989). Pneumonia is presented in nearly half of all melioidosis cases (Currie et al., 
2000; Meumann et al., 2012) and the acute form of melioidosis pneumonia resembles 
other types of bacterial pneumonia. Clinical and radiologic features of chronic 
pneumonia may also mimic pulmonary tuberculosis (Reechaipichitkul, 2004; 
Vidyalakshmi et al., 2008; White, 2003). Due to its protean manifestations, the 
infection is always termed “the great mimicker” (Yee et al., 1988). The varying clinical 
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patterns of melioidosis that lack distinct pathognomonic features often lead to 
inaccurate diagnosis and management of the disease.  
2.5.2 Disease transmission 
Infection is commonly acquired through direct contact with soil or muddy 
water, in which the pathogen enters the human body through skin wounds, cuts, or 
abrasion (Howe et al., 1971; Whitmore & Krishnaswami, 1912). Other routes of 
infection may include aspiration, inhalation of airborne dust or droplets, and ingestion 
of contaminated water (Currie et al., 2001; Dance, 2002). In Southeast Asia, the 
highest number of diagnosed cases were reported from Thailand (Chaowagul et al., 
1989; Leelarasamee, 2000; Vuddhakul et al., 1999), Malaysia (Hassan et al., 2010; 
Kingsley et al., 2016; Puthucheary et al., 1992; Vadivelu et al., 1997), and Singapore 
(Chan, Jayaratnam, & Teo, 1985; Lim et al., 1997; Tan, Ang, & Ong, 1990; Tong et 
al., 2009; Yap et al., 1991, 1995). Majority of the patients were farmers and 
agricultural workers who contracted the infection during their agricultural activities 
(Cheng & Currie, 2005; Reechaipichitkul, 2004). The marked seasonal incidence of 
melioidosis in endemic regions is influenced by seasonal rain and severe weather 
conditions, such as heavy monsoons, flooding, tsunamis, and typhoons which 
consequently increase the risk for potential exposure to the pathogen 
(Apisarnthanarak, Khawcharoenporn, & Mundy, 2012; Bulterys et al., 2018; 
Chierakul et al., 2005; Currie, Ward, & Cheng, 2010; Ko et al., 2007). Active tourism 
activities have also been linked to melioidosis infection in travelers who have visited 





2.5.3 Host risk factors  
Melioidosis is regarded as an opportunistic infection; hence, individuals with 
certain medical conditions, primarily those who are immunocompromised or 
immunosuppressed, are at greater risk of developing severe infections. Among the 
underlying risk factors for melioidosis include comorbidities such as diabetes mellitus, 
excessive alcohol consumption, impairment of the immune system, renal failure, 
chronic lung disease, steroid intake, malignancies, and thalassemia (Currie et al., 2000; 
Suputtamongkol et al., 1999). Seroprevalence studies indicate that B. pseudomallei 
infection is mostly asymptomatic, though it may quickly progress to a fatal illness in 
patients with comorbid factors (Ashdown & Guard, 1984; Cheng et al., 2008; 
Kanaphun et al., 1993; Wuthiekanun et al., 2006). The incubation period for 
melioidosis is generally one to 21 days after initial exposure, with a median of 9 days 
to the onset of infection; however, symptoms can rapidly develop within 24 hours with 
a high inoculum (Currie et al., 2000). In the case of latent infection, the incubation 
period may take months or years before clinical symptoms are apparent. The 
progression from asymptomatic infections to the onset of melioidosis usually depends 
on the host’s condition. The bacterium can remain latent inside the host for a long 
period of time and then reactivate when the infected person is immunocompromised 
(Currie et al., 2000). The longest documented period of latency from initial exposure 
to the onset of the disease is 62 years (Ngauy et al., 2005).  
2.5.4 Disease latency and relapse 
Recurrence of infection is a common feature of melioidosis, in which 5-28% 
of melioidosis patients have been reported to experience clinical relapse after a 
prolonged disease-free interval following the completion of antibiotic therapy 
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(reviewed in Wiersinga et al., 2018). Recrudescence can occur as a result of re-
exposure to other strain, or reactivation of the original strain which persisted in a 
dormant state and was not completely eradicated during previous treatment (Cheng & 
Currie, 2005; Currie et al., 2010; Maharjan et al., 2005; Suputtamongkol et al., 1993; 
Yee et al., 1988). Bacterial persistence is believed to be one of the causes for disease 
latency, antimicrobial treatment failure, and chronic recurrent infections. Several 
factors influencing B. pseudomallei persistence have been identified, including two-
gene toxin/antitoxin (TA) systems, metabolic enzymes, and adaptive mutations (Lewis 
& Torres, 2016). The TA systems mediate the formation of antibiotic tolerant variants, 
known as persisters, which form stochastically within a bacterial population in 
response to antimicrobial pressure (Harrison et al., 2009; Keren et al., 2004; Shah et 
al., 2006). When challenged with a lethal concentration of antibiotics, the TA modules 
encode a toxin that halts cell growth and lowers metabolic processes, which causes a 
small fraction of the clonal bacterial population to enter a transient state of dormancy 
(Christensen et al., 2004; van Melderen, Bernard, & Couturier, 1994). Since antibiotics 
generally target the actively growing cells, the formation of dormant persisters enables 
a subpopulation of the bacteria to tolerate and escape the effects of antibiotics (Keren 
et al., 2004). Nevertheless, much of the knowledge pertaining to the molecular 
mechanism of bacterial persistence still remains unclear. 
The capability of B. pseudomallei to remain in a dormant state is also attributed 
to its intracellular adaptation within the hosts. As a facultative intracellular pathogen, 
it is able to invade and multiply inside non-phagocytic (epithelial cells) and phagocytic 
cells (macrophages, leukocytes, monocytes, and neutrophils) (Egan & Gordon, 1996; 
Jones, Beveridge, & Woods, 1996; Pruksachartvuthi, Aswapokee, & Thankerngpol, 
1990). Following internalization, it can escape from the membrane-bound phagosome 
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into the cytosol (Stevens et al., 2002), where it subsequently polymerizes host actin to 
invade neighboring cells (Kespichayawattana et al., 2000). The actin-based 
intracellular motility enables the bacteria to move between cells effectively while 
avoiding host immune surveillance, which include the effector T cells, circulating 
antibodies, complement proteins, or other extracellular immune factors (Ray et al., 
2009). It has been suggested that the bacterium may also localize to the nucleus of 
infected cells and use the nuclear compartment as a protective niche for intracellular 
persistence (Vadivelu et al., 2017). 
2.5.5 Detection and identification of melioidosis 
Culture and isolation of B. pseudomallei from clinical specimens such as blood, 
urine, pus, skin lesions, sputum, or throat swab remains the gold standard for diagnosis 
of melioidosis (Anuntagool, Rugdech, & Sirisinha, 1993). Laboratory diagnosis can 
be difficult due to mixed variation in colony morphology that can lead to incorrect 
identification (Chantratita et al., 2007; Pumpuang et al., 2011). Besides, isolation from 
clinical samples often takes time and requires expertise, thus delaying initiation of 
treatment. Serological tests such as latex agglutination test or indirect 
haemagglutination test have lower sensitivity in general and are commonly performed 
for a provisional diagnosis. Enzyme-linked immunosorbent assay (ELISA) is a more 
convincing serological test (Ashdown et al., 1989). Conventional biochemical 
methods such as the API 20NE system provide an accurate identification in most of 
the cases (Amornchai et al., 2007); however, it can also misidentify the bacterium as 
Chromobacterium violaceum, Burkholderia cepacia or Pseudomonas aeruginosa 
(Inglis et al., 1998; Lowe, Engler, & Norton, 2002). Molecular identification 
techniques such as polymerase chain reaction (PCR), pulse field gel electrophoresis 
(PFGE), random amplification of particle of deoxyribonuclease (RAPD), and 
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restricted fragmentation length polymorphism (RFLP) are more reliable because of 
their high specificity, sensitivity, robustness and speed (Kunakorn et al., 2000; 
reviewed in Raja, Ahmed, & Singh, 2005; Rattanathongkom, Sermswan, & 
Wongratanacheewin, 1997). Nonetheless, these methods are not routinely accessible 
for clinical diagnosis. 
2.5.6 Treatment of melioidosis 
The course of treatment for melioidosis consists of two critical phases. The 
first one is the intensive acute phase, which typically involves short-term intravenous 
administration of ceftazidime, meropenem, or imipenem for an average duration of 10 
to 14 days; however, severe cases of infection may require longer period of treatment. 
The next phase of therapy is the eradication phase, which is initiated after positive 
improvements are seen in patients during the initial treatment. A combination of 
trimethoprim–sulfamethoxazole (TMP/SMX) is administered orally for at least three 
to six months, depending on the severity of the infection (Wiersinga et al., 2012). In 
the case of incompatibility or intolerance towards TMP/SMX, other antibiotics such 
as amoxicillin/clavulanic acid or doxycycline are recommended (Lipsitz et al., 2012). 
An optimum choice of drugs and the duration of antibiotic therapy are extremely 
crucial in avoiding mortality and preventing the relapse of melioidosis 
(Suputtamongkol et al., 1993). Treatment of B. pseudomallei also proves to be 
challenging due to its natural resistance to numerous antibiotics and the need for a 
lengthy course of biphasic antimicrobial therapy (Cheng & Currie, 2005; Woo et al., 
2003). The incidence of disease relapse and treatment failures still remain high despite 
the intensive course of recommended antibiotic therapy due to the bacterium’s 
antibiotic resistance machinery, intracellular survival, and ability to exist in a dormant 
state in the host for an extended duration (Dance et al., 1989; Schweizer, 2012a; 
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Suputtamongkol et al., 1993; Wong, Puthucheary, & Vadivelu, 1995). Many 
researches are currently focusing on the discovery and development of an effective 
vaccine for melioidosis prevention, however none has been commercially developed 
for clinical use so far (Cheng & Currie, 2005; Dowling, 2013; Peacock et al., 2012). 
2.6 Antibiotic resistance in B. pseudomallei 
The arsenal of antibiotics and therapeutic options available for the treatment of 
melioidosis are limited because of the intrinsic resistance of B. pseudomallei to wide 
classes of antimicrobial agents. B. pseudomallei is inherently resistant to various types 
of antibiotics such as β-lactams, macrolides, aminoglycosides, colistin, rifamycins, 
and older-generation cephalosporins ( Dance et al., 1989; Jenney et al., 2001). Several 
mechanisms of antibiotic resistance in B. pseudomallei have been previously 
documented, which include enzymatic inactivation (Godfrey et al., 1991; Livemore et 
al., 1987), target modification (Viktorov et al., 2008), low membrane permeability 
(Burtnick & Woods, 1999), and drug extrusion by multidrug efflux systems (Lipsitz 
et al., 2012; Moore et al., 1999; Schweizer, 2003).  
The lipopolysaccharide O-antigen and outer core components on the outer 
membrane of B. pseudomallei function as a permeability barrier to prevent the 
penetration of cationic compounds, thus contributing to its intrinsic resistance to 
antibiotics such as polymyxin B (Burtnick & Woods, 1999). PenA, a class A β-
lactamase, is accountable for primary resistance to β-lactams in most of the clinical 
isolates (Godfrey et al., 1991). PenA confers resistance to numerous β-lactam 
antibiotics such as amoxicillin, ampicillin and carbenicillin. It is chromosomally 
encoded by penA gene; in vitro deletion of penA causes the mutants to become fully 
susceptible to these antibiotics  (Rholl et al., 2011). Overexpression of PenA due to a 
